Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: United Therapeutics Corporation
Woman and Man Max 99 years
United Therapeutics Corporation
Update Il y a 4 ans
International, multicenter, randomized (1:1 oral treprostinil (UT-15C): placebo), double-blind, placebo-controlled study in subjects with Pulmonary Arterial Hypertension (PAH) who are receiving background oral monotherapy Studio internazionale, multicentrico, randomizzato (1:1 teprostinil (UT-15C) orale : placebo), in doppio cieco, controllato verso placebo, in soggetti con ipertensione arteriosa polmonare (PHA) che ricevono la monoterapia orale di background
1.To assess the effect of oral UT-15C with PAH approved oral monotherapy compared to placebo with PAH approved oral monotherapycompared to placebo with PAH approved oral monotherapy on time to first ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
United Therapeutics Corporation
Update Il y a 4 ans
An Open Label Extension Study of UT-15C in subjects with Pulmonary Arterial Hypertension
The primary objective of this study is to provide UT-15C sustained release tablets for eligible subjects who participated in TDE-PH-310 (A Phase III, International, Multi-Center, Randomized, Double-Bl...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
United Therapeutics Corporation
Update Il y a 4 ans
A 12-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary Arterial Hypertension
To assess the effect of UT-15C sustained release (SR) on exercise capacity compared to placebo (as measured by the change in 6-Minute Walk distance from Baseline to Week 12) in subjects with PAH who a...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
United Therapeutics Corporation
Update Il y a 4 ans
A 16-Week International, Multicenter, Double-Blind, Randomized, Placebo Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Combination with an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor in Subjects with Pulmonary Arterial Hypertension
To assess the effect of UT-15C sustained release (SR) on exercise capacity compared to placebo (as measured by the change in 6-Minute Walk distance from Baseline to Week 16) in subjects with PAH.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
United Therapeutics Corporation
Update Il y a 4 ans
Étude DIV-SCLC-301 : étude de phase 2 / 3 randomisée visant à comparer la sécurité d’emploi, la tolérance et l’efficacité du dinutuximab et de l’irinotécan avec l’irinotécan seul comme traitement de deuxième ligne chez des patients ayant un cancer du poumon à petites cellules récurrent ou réfractaire. [essai clos aux inclusions]
Le cancer du poumon à petites cellules prend naissance dans les cellules qui tapissent les bronches situées au centre des poumons. Il y a deux types principaux de cancer du poumon non à petites cellul...
Country
France
organs
Poumon, type à petites cellules
Specialty
Immunothérapie - Vaccinothérapie
,
Chimiothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
United Therapeutics Corporation
Update Il y a 4 ans
DISTOL-EXT:Digital Ischaemic Lesions in Scleroderma treated with Oral Treprostinil Diethanolamine: An open-label multicenter extension study
Provide, or continue to provide, treprostinil diethanolamine SR for eligible subjects who participated in protocols TDE-DU-201 or TDE-DU-301* * Protocol TDE-DU-301 is planned to be submitted at a...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
United Therapeutics Corporation
Update Il y a 6 ans
Étude DIV-SCLC-301 : étude de phase 2 / 3 randomisée visant à comparer la sécurité d’emploi, la tolérance et l’efficacité du dinutuximab et de l’irinotécan avec l’irinotécan seul comme traitement de deuxième ligne chez des patients ayant un cancer du poumon à petites cellules récurrent ou réfractaire.
Le cancer du poumon à petites cellules prend naissance dans les cellules qui tapissent les bronches situées au centre des poumons. Il y a deux types principaux de cancer du poumon non à petites cellul...
Country
France
organs
Poumon, type à petites cellules
Specialty
Immunothérapie - Vaccinothérapie
,
Chimiothérapie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
United Therapeutics Corporation
Update Il y a 4 ans
Double blind placebo controlled clinical investigation into the efficacy and tolerability of inhaled treprostinil in patients with severe pulmonary arterial hypertension
To determine the effects of chronically administered, inhaled Treprostinil Sodium (TRE) on exercise capacity with an un-encouraged 6-minute walk test (6MWT) in patients with pulmonary arterial hyperte...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
United Therapeutics Corporation
Update Il y a 4 ans
DISTOL-1:Digital Ischaemic Lesions in Scleroderma treated with Oral Treprostinil Diethanolamine: A randomized, double-blind, placebo controlled, multicenter study
To assess the efficacy of treprostinil diethanolamine on net ulcer burden compared to placebo in patients with systemic sclerosis (SSc)
Country
None
organs
None
Specialty
None
Closed trial
More information